RxDoctor Payments Data

Augustine Pyo

Internal Medicine · Los Angeles, CANPI 1255741005

Payments from drug & device makers

$1,496in general payments, 2019–2025

Across 57 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$378
  • Boston Scientific$178
  • Novo Nordisk$130
  • Johnson & Johnson$119
  • Lantheus Medical Imaging, Inc.$107
  • Edwards Lifesciences$107
  • plus $477 from 11 others

What the payments were for

  • Grants$1007%
  • Food & beverage$1,39693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,496 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$4,287
Medicare patients
39
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan35$54,975
EliquisApixaban19$18,550
PradaxaDabigatran Etexilate Mesylate61$16,661
Bisoprolol Fumarate84$1,880
Furosemide75$923
ClopidogrelClopidogrel Bisulfate31$599
Amiodarone Hcl17$495
Atorvastatin Calcium40$491
Potassium Chloride13$444
Metoprolol Tartrate28$397
Amlodipine Besylate34$386
Metoprolol Succinate29$330
Isosorbide Mononitrate ErIsosorbide Mononitrate23$304
Nitroglycerin11$293
Lisinopril18$229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$378$54,97535 claims
PfizerEliquis$22$18,55019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →